Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price reached a new 52-week low during trading on Tuesday. The company traded as low as C$0.02 and last traded at C$0.02, with a volume of 8,100 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Down 20.0%
The business has a fifty day moving average of C$0.02 and a 200 day moving average of C$0.03. The company has a market capitalization of C$3.38 million, a PE ratio of 0.68 and a beta of -0.61. The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35.
Quest PharmaTech Company Profile
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Featured Stories
- Five stocks we like better than Quest PharmaTech
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
